NYSE$STVN
Stevanato Group S.p.A. · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Stevanato Q4 2025: revenue rises 5% to €346.5M on high-value solutions strength
Stevanato Group reported fourth quarter 2025 revenue of €346.5 million, up 5% reported and 7% at constant currency, driven by 10% growth in the Biopharmaceutical and Diagnostic Solutions segment that offset a 23% decline in Engineering. High-value solutions revenue grew 31% to €171 million and represented 49% of total company revenue in the quarter. Q4 net profit was €47.6 million with diluted EPS of €0.17; adjusted net profit was €49.8 million and adjusted diluted EPS was €0.18. Adjusted EBITDA increased 7% to €97.7 million with a 28.2% margin. For full year 2025, revenue rose 7% to €1.186 billion with diluted EPS of €0.51 and adjusted diluted EPS of €0.54. Management issued 2026 guidance for revenue of €1.26–1.29 billion, adjusted EBITDA of €331.8–346.9 million, and adjusted diluted EPS of €0.59–0.63.
- Q4 revenue of €346.5M (+5% reported, +7% CC) with high-value solutions up 31% to €171M (49% of revenue).
- Q4 net profit of €47.6M and diluted EPS of €0.17; adjusted diluted EPS of €0.18 and adjusted EBITDA of €97.7M.
- Full-year 2025 revenue of €1.186B (+7%) with diluted EPS of €0.51 and adjusted diluted EPS of €0.54.
- GLP-1 related revenue accounted for 19–20% of total company revenue in 2025, growing more than 50% year-over-year.
- 2026 guidance: revenue €1.26–1.29B, adjusted EBITDA €331.8–346.9M, adjusted diluted EPS €0.59–0.63.
Headline financials
Revenue & EPS history
Stevanato Group · Revenue · Quarterly
€347M
Revenue by segment
Stevanato Group · €518M total across 3 segments · Q4 2025
- Biopharmaceutical and Diagnostic Solutions€307M+9.9%59.3%
- High-value solutions€171M+30.5%33.0%
- Engineering€39.4M-23.0%7.6%
Forward guidance
For fiscal 2026, Stevanato expects revenue of €1.26–1.29 billion, adjusted EBITDA of €331.8–346.9 million, and adjusted diluted EPS of €0.59–0.63, with BDS growing high single to low double digits and Engineering declining mid single to low double digits.
Tailwinds
- High-value solutions expected at 47–48% of total 2026 revenue with GLP-1 demand as a tailwind.
- Free cash flow expected to be breakeven to €20M positive in 2026 after turning positive in FY2025.
Headwinds
- Foreign currency translation expected to be an €18M headwind in 2026.
- Engineering segment revenue expected to decline mid single to low double digits.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2025
+1.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+3.0%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+22.3%
Q2 2021
Best reaction
-18.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +10.0% | +1.9% | -10.3% | |
| Q3 2025 | -1.7% | -3.3% | -11.6% | |
| Q2 2025 | -9.6% | -7.6% | -9.9% | |
| Q1 2025 | +2.9% | +12.0% | +8.9% | |
| Q4 2024 | +8.6% | +8.8% | +10.5% | |
| Q3 2024 | +16.4% | +12.4% | +3.9% | |
| Q2 2024 | +4.4% | +8.5% | +13.8% | |
| Q1 2024 | -18.9% | -20.7% | -30.8% | |
| Q4 2023 | -11.3% | -14.1% | -12.4% | |
| Q3 2023 | -5.9% | -2.5% | -3.5% | |
| Q2 2023 | +2.5% | +5.6% | +6.3% | |
| Q1 2023 | -3.3% | -1.5% | +2.6% | |
| Q4 2022 | +13.7% | +5.2% | +16.0% | |
| Q3 2022 | +0.4% | +9.1% | +18.0% | |
| Q2 2022 | +4.6% | -3.4% | -5.9% | |
| Q1 2022 | +0.7% | +8.7% | +11.2% | |
| Q4 2021 | -1.4% | -4.2% | +21.9% | |
| Q3 2021 | -8.7% | -11.2% | -4.8% | |
| Q2 2021 | +22.3% | +27.0% | +33.8% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro